2021
DOI: 10.1016/j.ygeno.2021.04.008
|View full text |Cite
|
Sign up to set email alerts
|

ACoRE: Accurate SARS-CoV-2 genome reconstruction for the characterization of intra-host and inter-host viral diversity in clinical samples and for the evaluation of re-infections

Abstract: Sequencing the SARS-CoV-2 genome from clinical samples can be challenging, especially in specimens with low viral titer. Here we report Accurate SARS-CoV-2 genome Reconstruction (ACoRE), an amplicon-based viral genome sequencing workflow for the complete and accurate reconstruction of SARS-CoV-2 sequences from clinical samples, including suboptimal ones that would usually be excluded even if unique and irreplaceable. The protocol was optimized to improve flexibility and the combination of technical replicates … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7
1

Relationship

4
4

Authors

Journals

citations
Cited by 10 publications
(16 citation statements)
references
References 63 publications
1
15
0
Order By: Relevance
“…COVID-19 diagnosis was performed by reverse-transcriptase real time PCR (RT-qPCR) on nasopharyngeal swab according to WHO guidelines (available at https://www.who.int/publications/ i/item/diagnostic-testing-for-sars-cov-2) and applying the CDC 2019-nCoV rRT-PCR Diagnostic Panel assay and protocol (available at https://www.fda.gov/media/134922/download) (21). IgG anti-SARS-CoV2 nucleocapsid protein (IgG-N) and IgM anti-SARS-CoV2 spike protein (IgM-S), were measured in patients' serum using a chemiluminescent microparticle immunoassays (CMIA) (Abbott, Ireland) following manufacturer's instructions.…”
Section: Sars-cov-2 Molecular and Serological Testsmentioning
confidence: 99%
“…COVID-19 diagnosis was performed by reverse-transcriptase real time PCR (RT-qPCR) on nasopharyngeal swab according to WHO guidelines (available at https://www.who.int/publications/ i/item/diagnostic-testing-for-sars-cov-2) and applying the CDC 2019-nCoV rRT-PCR Diagnostic Panel assay and protocol (available at https://www.fda.gov/media/134922/download) (21). IgG anti-SARS-CoV2 nucleocapsid protein (IgG-N) and IgM anti-SARS-CoV2 spike protein (IgM-S), were measured in patients' serum using a chemiluminescent microparticle immunoassays (CMIA) (Abbott, Ireland) following manufacturer's instructions.…”
Section: Sars-cov-2 Molecular and Serological Testsmentioning
confidence: 99%
“…RNA from 10 SARS-CoV-2 positive swab samples was extracted with STARMag 96 x 4 viral DNA/RNA 200 C kit * (Seegene, Seoul, Korea) and included in the ARTIC Network suggested v2 protocol ( 1 ) for viral genome sequencing. For each sample, 5 μl of purified RNA has been used for first-strand cDNA synthesis using SuperScript IV reverse transcriptase (Invitrogen, CA, USA) with modifications according to ( 9 ). Briefly, after the denaturation (65°C for 5 min followed by 1 min in ice) of the first mix - containing Random Examer (Invitrogen), dNTPs (Invitrogen), and the RNA - a second mix containing RT Buffer, 100 mM DTT, SuperScript-IV RT Enzyme, RNaseOUT (Invitrogen), and DEPC-treated water (Invitrogen) was added in a final volume of 20 μl.…”
Section: Methodsmentioning
confidence: 99%
“…The products were purified using a 0.9× ratio of AMPureXP beads (Beckman Coulter, Brea, CA, USA) and amplicons were eluted in 15 µL water. The positive control sample was a SARS-CoV-2 cDNA generated using primers 96F (5'-GCCAACAACAACAAGGCCAAAC-3') and 96R (5'-TAGGCTCTGTTGGTGGGAATGT-3') from the ARTIC v3 protocol [49]. We amplified 3ng cDNA in triplicate 50 µL reactions containing 10µM of each primer using Q5 High Fidelity DNA Polymerase (New England Biolabs).…”
Section: Amplicon Generationmentioning
confidence: 99%